Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.
Yang C, Brezden-Masley C, Joy AA, Sehdev S, Modi S, Simmons C, Henning JW. Yang C, et al. Among authors: joy aa. Ther Adv Med Oncol. 2023 Jun 5;15:17588359231175440. doi: 10.1177/17588359231175440. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37323186 Free PMC article. Review.
Models of care for early-stage breast cancer in Canada.
Madarnas Y, Joy AA, Verma S, Sehdev S, Lam W, Sideris L. Madarnas Y, et al. Among authors: joy aa. Curr Oncol. 2011 May;18 Suppl 1(Suppl 1):S10-9. doi: 10.3747/co.v18i0.898. Curr Oncol. 2011. PMID: 21698058 Free PMC article.
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, Johnson C, Lemieux J, Paterson I, Sebag IA, Simmons C, Sulpher J, Thain K, Thavendiranathan P, Wentzell JR, Wurtele N, Côté MA, Fine NM, Haddad H, Hayley BD, Hopkins S, Joy AA, Rayson D, Stadnick E, Straatman L. Virani SA, et al. Among authors: joy aa. Can J Cardiol. 2016 Jul;32(7):831-41. doi: 10.1016/j.cjca.2016.02.078. Epub 2016 Apr 7. Can J Cardiol. 2016. PMID: 27343741 Review.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Targeting HER2 in Advanced Breast Cancer.
Zhu X, Joy AA. Zhu X, et al. Among authors: joy aa. Methods Mol Biol. 2017;1652:63-77. doi: 10.1007/978-1-4939-7219-7_4. Methods Mol Biol. 2017. PMID: 28791634 Review.
132 results